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DOCETAXEL-BASED CHEMOTHERAPY IN 
HIGH-RISK LOCALISED PROSTATE 
CANCER (PCA): UPDATED RESULTS 
FROM THE GETUG12 PHASE III TRIAL
GETUG-12 assessed docetaxel-estramustine in patients 
with high-risk localised PCa. A benefit in relapse-free sur-
vival (RFS) was reported previously.1 Updated RFS and as-
sessment of clinical events were presented during ESMO 
2018. A total of 413 patients with high-risk localised PCa 
(treatment-naïve + ≥ 1 of the following: T3-T4, Gleason ≥8, 
PSA ≥20 ng/mL, pN+) were randomised to LHRH agonist 
goserelin for 3 years + 4 cycles of docetaxel 70 mg/m2 + es-
tramustine 10 mg/kg/day on days 1-5 q3w (ADT+DE arm) 
or goserelin alone (ADT arm). Local therapy (radiothera-
py in 87% of cases) was given at 3 months. After 12 years 
of follow-up, an event was observed in 233 patients (56%). 
The twelve-year RFS rate was significantly improved in the 
ADT+DE arm as compared to the ADT arm: 49% vs. 36% 
(HR: 0.71, p= 0.011; Figure 1) with a median RFS of 11.6 and 
8.1 years, respectively. Subgroup analyses demonstrated a 
beneficial effect for poor risk tumours (T3-T4, PSA≥20 ng/
mL, pN+) except for patient with high Gleason scores. In ad-
dition, also the clinical RFS was also significantly improved 
with ADT+DE (13.9 vs. 12.5 years; HR: 0.75; p= 0.049; Fig-
ure 1). The twelve-year metastases-free survival rates (62.2% 
vs. 55.8%) and 12-year PCa-specific survival rates (88.2% vs. 
83.9%) did not differ significantly between the two study 
arms. 
In conclusion, 4 cycles of docetaxel-based chemothera-
py reduce the risk of clinical relapse or death in men with 
high-risk localised PCa although this provides no benefit for 
metastases-free and PCa-specific survival.2
TREATMENT REGIMENS FOR 
METASTATIC CASTRATION-RESISTANT 
PROSTATE CANCER (MCRPC): WHAT’S 
NEW?
Abiraterone acetate (AA) is known to improve the pro-
gression-free (PFS) and overall survival (OS) in men with 
mCRPC. Ra-223 also increases the OS and decreases 
symptomatic skeletal events (SSE) in men with mCRPC 
and bone metastases. In the ERA223 phase III trial, the 
concurrent treatment with AA and Ra-223 was evaluat-
ed in asymptomatic / mildly symptomatic men with che-
motherapy-naïve mCRPC and bone metastases. In total, 
806 patients were randomised (1:1) to AA + Ra-223 (N= 
401) or AA + placebo (N= 405). Following the complete 
study-specified Ra-223/placebo treatment, the trial was 
unblinded as more fractures and deaths were observed in 
the AA + Ra-223 arm. At the primary analysis, the medi-
an SSE-free survival (22.3 vs. 26.0 months) and the median 
OS (30.7 vs. 33.3 months) were not significantly different 
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FIGURE 1. Survival outcome of LHRH agonist goserelin for 3 years plus 4 cycles of docetaxel + estramustine vs goserelin 
alone for high-risk localized PCa. RFS is depicted on the left; clinical RFS is depicted on the right.2
Median RFS:
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HR=0.75 (0.560;0.999)
p=0.0491
between Ra-223 and placebo. No benefits were found for 
other exploratory endpoints. Fractures occurred in 29% 
and 11% of patients for Ra-223 and placebo, respectively, 
with more fractures observed in patients who did not re-
ceive bone health agents at baseline. Based on the safety 
and survival results, the combination of AA and Ra-223 
is not recommended for the treatment of asymptomatic / 
mildly symptomatic bone-predominant mCRPC.3
The optimal treatment for poor prognosis mCRPC is unde-
fined and includes either taxane chemotherapy or androgen 
receptor (AR) targeted therapy, emphasizing the need for 
predictive biomarkers. A presented phase II trial compared 
cabazitaxel (CABA) with AA or enzalutamide (ENZ) in this 
setting and looked for any genomic correlations with the 
treatment outcome. Patients with poor prognosis mCRPC 
(i.e. liver metastases, early CRPC [<12 months from ADT 
start], and/or >3 of 6 poor prognostic criteria4) were ran-
domised to receive CABA (N= 45) or AA/ENZI (N= 50) with 
cross over at progression. No prior AA or ENZ use was per-
mitted. The median duration of therapy was 5.8 with CABA 
as compared to 4.5 months with AA/ENZ. Treatment dis-
continuation reasons included disease progression (40% vs. 
46%) and toxicity (11% vs. 4%). The clinical benefit rate was 
higher with CABA than what was seen with AA/ENZ (90% 
vs. 70%, p= 0.02). No difference was observed in terms of 
PSA decline ≥50% (56% vs. 60%), objective response rate 
(ORR) (11% vs. 12%), time to progression (5.3 vs. 4.1 months) 
and OS (not reached vs. 15.5 months). The baseline circu-
lating tumour DNA (ctDNA) fraction (30-100%; 2-30% and 
undetected) was found to be correlated with both the time 
to progression (medians 2.8, 5.3 and 8.6 months; respective-
ly) and the OS (medians 9.9, 22.0 months and not reached, 
respectively). Furthermore, an on-treatment change in the 
ctDNA fraction appeared also had prognostic value for both 
PFS and OS (p= 0.001). In addition, AR amplification num-
ber showed no effect towards treatment choice. 
Based on these findings, no definitive treatment choice can 
be selected for poor prognosis mCRPC patients as CABA and 
AA/ENZ resulted in similar outcomes. The study did reveal 
that ctDNA has potential as a prognostic factor in these pa-
tients, but this needs further validation.5 
TREATMENT OF NEWLY HORMONE 
SENSITIVE mPCa: WHAT TO CHOOSE?
Based on the LATITUDE trial6 AA is licenced in the EU for 
use in high risk newly diagnosed hormone sensitive mPCa, 
despite contradictory outcomes in the STAMPEDE trial.7 A 
study presented at ESMO 2018 retrospectively evaluated the 
heterogeneity of AA on OS and failure-free-survival (FFS) in 
patients with LATITUDE defined high & low-risk metastat-
ic disease who were randomised to ADT or ADT + AA in the 
STAMPEDE trial. Staging scans of 901 eligible patients were 
evaluated centrally for patients randomised to ADT or ADT 
+ AA. Patients were classified as low (N= 428) or high risk 
(N= 473) according to the LATITUDE criteria. A secondary 
differential analysis by tumour volume (high/low) was do-
ne using the criteria defined in CHAARTED. The median 
follow-up for this analysis was 41.5 months. Patients treat-
ed with ADT + AA showed clinically and statistically signif-
icant FFS and OS improvements in both high- (HR
FFS
 = 0.31 
[95%CI: 0.25-0.39]; HR
OS
 = 0.54 [95%CI: 0.41-0.70]) and low- 
(HR
FFS
 = 0.24 [95%CI: 0.17-0.33]; HR
OS
 = 0.66 [95%CI: 0.44-
0.98]) risk groups. In addition, benefits were also observed 
in terms of PCa-specific survival. No evidence of heteroge-
neity was detected between risk groups. Similar results were 





In addition, it was hypothesised that local radiotherapy could 
improve the OS of men presenting with hormone sensitive 
mPCa, especially in men with low metastatic burden. In the 
STAMPEDE trial, 2061 men with newly-diagnosed mPCa 
were randomised (1:1) to ADT (with early docetaxel) or ADT 
+ radiotherapy (55Gy/20f/4w or 36Gy/6f/6w). Metastatic bur-
den was well balanced (40% low, 54% high, 6% unknown). 
Local radiotherapy was found to improve the FFS (HR[95%-
CI]: 0.76[0.68-0.84]) but not the OS (HR[95%CI]: 0.92[0.80-
1.06]). Further analyses highlighted an increased OS in 
patients with low metastatic burden (HR[95%CI]: 0.68[0.52-
0.90]) but this was not the case in the subgroup of patients 
with a high metastatic burden (HR[95%CI]: 1.07[0.90-1.28]). 
No difference between both arms was observed in time from 
randomisation to next life-prolonging treatment nor in time 
from randomisation to first symptomatic local event. Local 
radiotherapy was well tolerated with only 5% grade 3/4 ad-
verse events (AEs).9
FIGURE 2. Survival outcome between avelumab + axitinib and sunitinib for first-line treatment of advanced RCC. PFS is 
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Based on these results, ADT + local radiotherapy could be 
offered to patients presenting with oligometastatic hormone 
sensitive PCa. On the other hand, adding AA to ADT in the 
same patient population shows a significant benefit in out-
come, irrespective of risk classification.
IMMUNOTHERAPY AS FIRST-LINE 
TREATMENT FOR ADVANCED RENAL 
CELL CARCINOMA (RCC)?
A phase Ib trial of first-line avelumab + axitinib showed en-
couraging antitumour activity for patients with advanced 
RCC.10 The outcome with this treatment regimen was fur-
ther evaluated in the phase III JAVELIN trial. A total of 886 
patients (clear-cell, ECOG ≤ 1, no prior systemic therapy) 
were randomised (1:1) to avelumab (10 mg/kg IV q2w) plus 
axitinib (5 mg PO BID) or sunitinib (50 mg PO QD q4/6w). 
Patients were stratified according to IMDC risk criteria (fa-
vourable 21%, intermediate 62%, poor 16%). The ORR was 
51% with the avelumab-axitinib combination as compared 
to 26% with sunitinib (p< 0.001). The median PFS was 
13.8 months with the immunotherapy-containing regimen, 
which was significantly longer than the 8.4 months median 
PFS seen with sunitinib (HR[95%CI]: 0.69[0.56-0.84]; Figure 
2). Among patients with PD-L1+ tumours (≥ 1% of immune 
cells), the ORR was significantly higher in the avelumab + 
axitinib arm compared to sunitinib (55% vs. 26%) and the 
median PFS was almost twice as long with the experimental 
regimen (13.8 vs. 7.2 months; HR[95%CI]: 0.61[0.48-0.79]; 
Figure 2). This PFS benefit was seen irrespective of IMDC risk 
criteria. At the time of the presentation, the OS data were 
not yet mature. The incidence of grade 3/4 AEs was compa-
rable in both arms (71.2% vs. 71.5%), although a higher rate 
of treatment discontinuation was observed with avelumab 
+ axitinib arm (22.8% vs. 13.4%). Nevertheless, due to the 
promising results avelumab + axitinib can be considered as 
a first-line treatment option provided that a beneficial result 
for OS is found.11
Atezolizumab + bevacizumab previously demonstrated to in-
duce an improved PFS as compared to sunitinib in the first-
line treatment of patients with mRCC expressing PD-L1.12 
The hypothesis that RNA gene expression signatures could 
be associated with a differential outcome to therapy was test-
ed in the IMmotion 151 trial and the results of this anal-
ysis were presented at ESMO 2018. In this study, patients 
were randomised (1:1) to atezolizumab (1200mg IV q3w) + 
bevacizumab (15mg/kg IV q3w) (N= 454) or sunitinib (50 
mg PO QD q4/6w) (N= 461). Tumour gene expression was 
performed in 823 patients. Both the angiogenesis and T
effector
 
gene expression signatures were distributed equally accord-
ing to MSKCC risk groups. The median PFS was longer with 
atezolizumab + bevacizumab than with sunitinib both in the 
PD-L1+ patients (11.2 vs. 7.7 months; HR[95%CI]: 0.74 [0.57-
0.96]) as in the intention-to-treat (ITT) population (11.2 vs. 
8.4 months; HR[95%CI]: 0.83[0.70-0.97]; Figure 3). This PFS 
benefit was seen irrespective of MSKCC risk status and was 
particularly pronounced in patients with sarcomatoid tu-
mour types. Subdividing according to the angiogenesis gene 
expression resulted in an improved PFS outcome for atezoli-
zumab + bevacizumab in the angiogenesisLow group but not 
in the angiogenesisHigh group. Furthermore, focussing within 
each treatment arm, the PFS was higher for angiogenesisHigh 
patients versus angiogenesisLow patients treated with suni-
tinib, whereas no difference in PFS outcome was found in 
the atezolizumab + bevacizumab arm according to the angio-
genesis gene expression signature. Vice versa, looking at the 
T
effector
 gene expression resulted in an improved PFS outcome 
FIGURE 3. PFS outcome between atezolizumab + bevacizumab and sunitinib for first-line treatment of advanced RCC. PFS 
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Low in each treatment arm. 
These results validate molecular signatures that differentiate 
clinical outcomes with VEGF inhibition and immunothera-
py. This represents a next step towards personalised therapy 
in patients with mRCC. Further validation of these findings 
is warranted.13 
ADJUVANT AXITINIB FOR HIGH RISK OF 
RECURRENT RCC: OUTCOME IN THE 
PHASE III ATLAS TRIAL
Axitinib is approved as second-line treatment for patients 
with advanced RCC. The question remains if this targeted 
therapy could also be used as an adjuvant therapy in RCC 
with high risk of recurrence. In the study at hand, 724 pa-
tients with RCC (nephrectomy; >50% clear-cell RCC; no re-
FIGURE 4. Survival outcome between nivolumab NIVO3, NIVO3/IPI1 and NIVO1/IPI3 for platinum pre-treated mUC. PFS is 







































































































































































































































































sidual disease or mRCC) were randomised (1:1) to receive 
axitinib 5 mg PO BID (n=363) or placebo (n=361) for up to 
3 years. Dose alterations were allowed. Most patients were 
Asian (73%), their median age was 58 years and highest risk 
was defined as pT3 with Fuhrman grade ≥3 or pT4 and/or N1 
with any Fuhrman grade (57%). No difference in disease-free 
survival was observed, neither for the ITT population (both 
not reached; HR[95%CI]: 0.87[0.66-1.15]) nor for the pre-
defined high-risk patients (both not reached; HR[95%CI]: 
0.74[0.53-1.03]). OS data were immature at time of the in-
terim analysis. Notably, more AEs (98.6% vs. 92.5%), serious 
AEs (19.4% vs. 14.5%), grade 3/4 AEs (61.2% vs. 30.1%), dose 
reductions (56.2% versus 8.4%), dose interruptions (51.4% vs. 
21.7%) and treatment discontinuations due to AEs (23.3% vs. 
11.1%) were seen with axitinib than with placebo, with hy-
pertension being the most common AE. 
In retrospect to these findings, axitinib should not be con-
sidered as adjuvant therapy for patients with RCC at high 
risk of recurrence.14
CHECKPOINT INHIBITION IN UROTHELIAL 
CANCER (UC): RECENT FINDINGS
Combination of checkpoint inhibitors is promising in sev-
eral malignancies. Early results from the phase I/II Check-
Mate 032 trial in platinum-pre-treated mUC have proven 
effective.15 At ESMO 2018 results from the expanded cohorts 
and extended follow-up data were presented. Patients (previ-
ously platinum-treated, measurable disease, ECOG ≤1) were 
randomised to nivolumab (3mg/kg q2w) (NIVO3, N= 78), 
nivolumab (3mg/kg) + ipilimumab (1mg/kg q3w for 4 cycles) 
followed by nivolumab (3mg/kg q2w) (NIVO3/IPI1, N= 104), 
or nivolumab (1mg/kg) + ipilimumab (3mg/kg q3w for 4 cy-
cles) followed by nivolumab (3mg/kg q2w) (NIVO1/IPI3, N= 
92) until disease progression or unacceptable toxicity. The re-
ported ORR was 26%, 27%, and 38% for NIVO3, NIVO3/IPI1 
and NIVO1/IPI3, respectively, with ongoing responses in 
45%, 46% and 66% of patients. The ORR was similar among 
patients with PD-L1+ (≥1%) and PD-L1– tumours for NIVO3 
(27% vs. 26%) and NIVO3/IPI1 (35% vs. 25%) but differed 
KEY MESSAGES FOR CLINICAL PRACTICE
1.   Concurrent docetaxel and ADT for high risk localised PCa has no impact on PCa-specific survival and is 
therefore not considered as viable treatment.
2.   Concurrent abiraterone acetate and Ra-223 for (a)symptomatic bone-predominant mCRPC is not recom-
mended due to lack in survival outcome and a worse safety profile.
3.   No clear treatment choice exists for AR targeted therapy-naïve poor risk mCRPC as non-inferiority for 
cabazitaxel vs. abiraterone acetate/enzalutamide was observed.
4.   ctDNA fraction might be of use as a prognostic marker for treatment of poor-risk mCRPC although further 
validation is warranted.
5.   Abiraterone acetate + ADT is usable in high-risk, newly diagnosed hormone sensitive mPCa, irrespective 
of LATITUDE, STAMPEDE or CHAARTED criteria. 
6.   Both avelumab + axitinib and atezolizumab + bevacizumab yield encouraging results as first-line therapy 
for mRCC. This further complicates the first-line treatment choice in this setting. Extensive prospective 
comparison of newly available first-line regimens is therefore warranted.
7.   Gene expression signatures for differential outcome in mRCC could be used in several subgroups alt-
hough further research is still needed.
8.   Adjuvant axitinib is not advised for high risk recurrent RCC as no survival benefit is observed with an 
increase in toxicity profile.
9.   Checkpoint inhibition is a valid treatment option in mUC. Furthermore, combination of checkpoint inhi-
bitors (nivolumab + ipilimumab) is effective in platinum pre-treated mUC with a manageable safety profile. 





significantly for NIVO1/IPI3 (58% vs. 24%). Next, the medi-
an PFS (4.9 vs. 2.8 vs. 2.6 months) and median OS (15.3 vs. 9.9 
vs. 7.4 months) were also longer with NIVO1/IPI3 than with 
NIVO3 and NIVO3/IPI1 (Figure 4). Grade 3/4 treatment-re-
lated AEs occurred in 27%, 31% and 39% of patients for NI-
VO3, NIVO3/IPI1 and NIVO1/IPI3, respectively. 
These results show efficacy of all investigated treatment reg-
imens, with favour for NIVO1/IPI3, in platinum pre-treated 
mUC with manageable safety profile. A large phase III trial is 
currently ongoing to compare NIVO1/IPI3 with chemothera-
py in previously untreated mUC (CheckMate 901).16
Finally, it has been hypothesised that activation of the PD-
1/PD-L1 axis is involved in resistance to Bacillus Calmette-
Guérin (BCG) therapy. This hypothesis was tested in patients 
with BCG-unresponsive non–muscle invasive bladder can-
cer who were treated with checkpoint inhibition. At the time 
of the analysis, 103 patients (BCG-unresponsive, carcino-
ma-in-situ ± papillary disease, adequate BCG therapy, no 
radical cystectomy) were enrolled in the single-arm phase II 
KEYNOTE-057 trial and received pembrolizumab 200 mg 
q3w for 24 months or until recurrence, progression, or un-
acceptable toxicity. At first radiographic evaluation (includ-
ing 97 evaluable patients) the complete response (CR) rate 
was 39%. The median duration of response was not reached 
and 80% of patients had an ongoing response duration of 
6 months or more. Treatment-related AEs occurred in 65 pa-
tients (immune-mediated in 15 patients), with pruritus (11%), 
fatigue (10%) and diarrhoea (9%) being the most common. 
Treatment-related grade 3-5 AEs occurred in 13 patients with 
1 treatment-related death. 
Given to the encouraging anti-tumour activity of pembroli-
zumab in this setting, the aforementioned hypothesis might 
be valid and pembrolizumab could be an ideal treatment op-
tion in this patient population. Further research is warranted 
as the KEYNOTE-057 is ongoing. A phase III trial (KEY-
NOTE-676) with a similar patient population is planned.17
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